John Lazo (VaDDC, Univ. of Virginia Pharmacology), David Kingston (VaDDC, Virginia Tech Chemistry) and Thomas Loughran (Director, Univ. of Virginia Cancer Center) were interviewed by Charlottesville’s CBS affiliate regarding Virginia Drug Discovery Consortium’s 2017...

Professor Rob Gourdie, Director of the Virginia Tech Carilion Research Institute’s (VTCRI) Center for Heart and Regenerative Medicine Research, previously founded First String Research Inc., which is poised to commercialize a treatment for debilitating foot ulcers in...

A team headed by Paul Carlier, Professor of Chemistry, Virginia Tech has received funding from the National Institutes of Health to carry out lead optimization on antimalarial drug candidate MMV008138. Carlier, who is Deputy Director of the Virginia Tech Center for...

Milton L. Brown, MD, PhD, has recently joined Inova. He will serve as director of the new Inova Center for Drug Discovery and Development and as deputy director for Drug Discovery for the Inova Schar Cancer Institute (ISCI). Dr. Brown is a physician scientist who has...

Virginia Tech scientists have developed a cancer drug that increases the effectiveness of a common chemotherapy treatment and dramatically reduces devastating side effects, such as hair loss, nausea, and nerve pain. The new drug uses gold nanoparticles created by the...

Potential new treatments for radiation exposure: The investigators exploited an optimized, cell-based,high throughput screening assay to interrogate a small
molecule library comprising 3437 known pharmacologically
active compounds for mitigation against IR-induced...

The need for new antimalarial drugs is dire, and this work identifies attractive lead compounds for drug development as well as important probes for dissecting a key antimalarial drug target, the non-mevalonate pathway for isoprenoid biosynthesis. This pathway does...